CONRAY 43 Rx
Generic Name and Formulations:
Iothalamate meglumine 430mg/mL; soln for IV infusion; organically bound iodine 202mg/mL.
Indications for CONRAY 43:
For use in lower extremity venography, IV infusion urography, contrast enhancement of computed tomographic brain images and arterial digital subtraction angiography. For enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space. For use in retrograde cystography, cystourethrography and retrograde pyelography.
Adults and Children:
Lower extremity venography: 30–125mL per lower extremity; reduce dose in children based on body weight. IV infusion urography: infuse at a rate of 40–50mL/min. 3mL/kg; max 200mL. Non-neoplastic conditions: 3mL/kg IV; max 200mL. Contrast enhanced in body computed tomography: 200–250mL by bolus inj, rapid infusion or combination of both; children: reduce dose based on body weight. Arterial digital subtraction aniography: Carotid or vertebral arteries: 3–10mL; Aortic arch: 15–30mL; Subclavian and brachial arteries: 5–15mL; Major branches of the aorta: 5–30mL; Abdominal aorta: 10–30mL; max 200mL. Retrograde pyelography: 25mL for bilateral and 15mL for unilateral pyelograms; about 5–6mL are usually administered for each exposure; children: usually require a volume reduced in proportion to body size. Cystography and cystourethrography: adults: 200–400mL; children: 30–300mL.
Myelography. Others: see full labeling.
Not for intrathecal use.
Not for intrathecal use. Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Avoid in homocystinuria. Subarachnoid hemorrhage. Multiple myeloma. Pheochromocytoma. Homozygous sickle cell disease. Primary or metastatic cerebral lesions; risk of convulsions. Advanced renal disease. Combined renal and hepatic disease. Severe hypertension. CHF. Recent renal transplant. Diabetes. Diabetic nephropathy. Hyperthyroidism. Endotoxemia. Elevated body temperatures. History of asthma/allergy. Elderly. Maintain adequate hydration. Pregnancy (Cat.B - Conray 30, 60; Cat.C - Conray 43). Nursing mothers: not recommended; avoid breastfeeding for 24hrs post-procedure.
Radiopaque contrast medium.
GI upset, facial flushing, body warmth; hypersensitivity reactions, cardiovascular reactions (eg, vasodilation, flushing, venospasm), inj site reactions, neurological reactions (eg, spasm, convulsions, aphasia, syncope, coma, death), endocrine reactions (eg, hypothyroidism), headache, shaking, chills, nephropathy.
Conray 30: Bottles (150mL)—12; Conray 43: Vials (50mL)—50; Bottles (250mL)—12; Conray 60: Vials (30mL, 50mL)—50; Bottles (100mL, 150mL)—12
Renal and Urology News Articles
- Phosphate Binders Lower Infection-Related Death Risk in HD
- Acute Renal Failure in CKD Patients Less Likely With PCI
- Gout Associated With Increased Risk of Developing Erectile Dysfunction
- More Targeted Sodium Reduction Strategies Proposed
- Cytoreductive Surgery for Metastatic PCa Linked to More Complications
- FDA Recalls Drugs Containing Active Ingredient Valsartan
- Correcting Metabolic Acidosis May Preserve Muscle Mass
- Infection Risk Lower in Dialysis Patients With High, Normal Vitamin D
- Urine Cytology May Not Improve Hematuria Evaluation for Bladder Cancer
- Aggressive Therapy Warranted for Gleason 10 Prostate Cancer
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)